Patents Assigned to VenatoRx Pharmaceuticals, Inc.
  • Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
    Patent number: 11820784
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: November 21, 2023
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Luigi Xerri, Timothy Henkel, Daniel McGarry, Lawrence Rosen, Gerald Brenner, Jean-Baptiste Arlin, Ana Fernandez Casares
  • Orally-bioavailable nucleoside analogs
    Patent number: 11638715
    Abstract: Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: May 2, 2023
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Guo-Hua Chu, Stephen M. Condon, Steven A. Boyd, Daniel C. Pevear
  • Hepatitis B capsid assembly modulators
    Patent number: 11566001
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 31, 2023
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
  • Boron-containing compounds
    Patent number: 11560392
    Abstract: Described herein are boron-containing compounds, compositions, and methods for their preparation.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: January 24, 2023
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Franz Amann, Matthew M. Bio, Jonas Bürgler, Yuanqing Fang, David Ford, Daniel McGarry
  • Beta-lactamase inhibitors
    Patent number: 11414435
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: August 16, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Penicillin-binding protein inhibitors
    Patent number: 11332485
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 17, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Jodie Hamrick, Matthew Lucas, Steven A. Boyd, Allison L. Zulli, Eugen F. Mesaros, Stephen M. Condon, Robert E. Lee Trout, Cullen L. Myers
  • Penicillin-binding protein inhibitors
    Patent number: 11267826
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 8, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Randy W. Jackson, Jodie Hamrick, Matthew Lucas, Steven A. Boyd, Jiangchao Yao, Eugen F. Mesaros
  • Hepatitis B capsid assembly modulators
    Patent number: 11247965
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: February 15, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon
  • Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
    Patent number: 11091505
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 17, 2021
    Assignee: VenatoRx Pharmaceuticals, Inc.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Luigi Xerri, Timothy Henkel, Daniel McGarry, Lawrence Rosen, Gerald Brenner, Jean-Baptiste Arlin, Ana Fernandez Casares
  • Beta-lactamase inhibitors
    Patent number: 11046716
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 29, 2021
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Bin Liu, Jiangchao Yao, Denis Daigle, Steven A. Boyd
  • HEPATITIS B CAPSID ASSEMBLY MODULATORS
    Publication number: 20210171439
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 10, 2021
    Applicant: VenatoRx Pharmaceuticals, Inc.
    Inventors: Christopher J. BURNS, Glen COBURN, Bin LIU, Jiangchao YAO, Christopher BENETATOS, Steven A. Boyd, Stephen M. CONDON
  • Hepatitis B capsid assembly modulators
    Patent number: 11014881
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 25, 2021
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
  • Beta-lactamase inhibitors
    Patent number: 11008346
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: May 18, 2021
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Boron-containing compounds
    Patent number: 10889600
    Abstract: Described herein are boron-containing compounds, compositions, and methods for their preparation.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: January 12, 2021
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Franz Amann, Matthew M. Bio, Jonas Bürgler, Yuanqing Fang, David Ford, Daniel McGarry
  • Beta-lactamase inhibitors
    Patent number: 10669290
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: June 2, 2020
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Hepatitis B capsid assembly modulators
    Patent number: 10590076
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 17, 2020
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
  • Beta-lactamase inhibitors
    Patent number: 10464952
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 5, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson, Jodie Hamrick, Allison L. Zulli, Eugen F. Mesaros, Steven A. Boyd
  • Beta-lactamase inhibitors
    Patent number: 10399996
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 3, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Bin Liu, Jiangchao Yao, Denis Daigle, Steven A. Boyd
  • Beta-lactamase inhibitors
    Patent number: 10294248
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 21, 2019
    Assignee: VenatoRx Pharmaceuticals, Inc.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Beta-lactamase inhibitors
    Patent number: 10294247
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: May 21, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout